|
|
|
|
|
|
|
|
|
18.12.25 - 12:15
|
Vantage Group Holdings to be acquired by Howard Hughes Holdings (PR Newswire)
|
|
|
Vantage's Diversified Specialty Insurance Platform Delivers Lower Risk and Superior Return Potential HHH to Host a Conference Call and Presentation on Thursday, December 18 at 8:30 a.m. ET, With an X Spaces Session to Follow HAMILTON, Bermuda, Dec. 18, 2025 /PRNewswire/ -- Vantage Group......
|
|
|
18.12.25 - 12:06
|
Pershing Square Holdings, Ltd. Announces Investment in Howard Hughes Holdings Inc. Preferred Stock (Business Wire)
|
|
|
LONDON--(BUSINESS WIRE)--Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announces that it has entered into an equity commitment letter to subscribe for up to $1 billion of non-voting exchangeable perpetual preferred stock to be issued by Howard Hughes Holdings Inc. (NYSE: HHH) (“HHH”) (the “PSH Preferred”) (the “PSH Investment”) in connection with HHH's agreement to indirectly acquire Vantage Group Holdings, Ltd. (“Vantage”), a privately held specialty insurance and reinsurance company being sold by, among others, Carlyle and Hellman & Friedman, for approximately $2.1 billion in cash. HHH's announcement of its agreement to acquire Vantage is available here https://investor.howardhughes.com/news-events/news-releases.
The board of directors of PSH (the “PSH Board”) note the views of HHH's management in relation to the Vantage acquisition and believe that it offers attractive prospects for HHH and, accordingly, for PSH, HHH's largest shareholder, and its sharehold...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 22:18
|
Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
|
|
|
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee.
“I am very pleased to welcome Bill to our board of directors,” said Ari Bousbib, chairman and CEO, IQVIA. “Bill is a world-renowned scientist and physician with deep e...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
